Drug Trial Radar · NCT07380386
SKB105 for Injection in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
256
Planned (sponsor's estimate)
Start
Mar 5, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 clinical study to evaluate the safety and efficacy of SKB105 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.
Conditions
- Advanced Solid Tumors
Interventions
SKB105 for injection MonotherapyDrug
SKB105 for injection monotherapy, iv drip, every 3 weeks (Q3W), until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects achieving Dose-limiting toxicity (DLT)Time frame: From date of initial dose until up to 21 days for treatment
- Objective Response Rate (ORR)Time frame: up to 3 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Shangahi Chest Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.